Beactica Therapeutics and University of Dundee announce collaboration to develop WRN inhibitors to target cancer
Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, today announced a new research collaboration agreement. The two parties will work together in a project aimed at inhibiting WRN helicase, a protein with significant therapeutic potential for cancers with microsatellite instability. The collaboration will leverage core capabilities of each partner and build on the work of Professor John Rouse, on the control of chromosome stability and DNA repair in cancer. Beactica will contribute key